Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.77% | 19.18% | 9.95% | 5.74% | 7.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.77% | 19.18% | 9.95% | 5.74% | 7.52% |
| Cost of Revenue | 24.70% | 15.92% | 5.46% | 2.09% | 2.80% |
| Gross Profit | 33.01% | 21.28% | 12.97% | 8.23% | 10.78% |
| SG&A Expenses | -0.34% | -6.96% | -3.17% | -6.33% | -8.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.19% | 3.03% | 1.08% | -2.06% | -2.97% |
| Operating Income | 403.28% | 237.99% | 106.50% | 73.82% | 66.09% |
| Income Before Tax | 513.21% | 279.32% | 122.95% | 79.19% | 67.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 499.80% | 273.15% | 122.95% | 79.19% | 67.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 499.80% | 273.15% | 122.95% | 79.19% | 67.03% |
| EBIT | 403.28% | 237.99% | 106.50% | 73.82% | 66.09% |
| EBITDA | 513.99% | 286.83% | 122.21% | 81.96% | 71.27% |
| EPS Basic | 489.15% | 268.89% | 122.52% | 79.59% | 69.20% |
| Normalized Basic EPS | 500.34% | 274.33% | 122.32% | 84.79% | 74.24% |
| EPS Diluted | 414.77% | 241.06% | 110.89% | 74.89% | 65.98% |
| Normalized Diluted EPS | 478.31% | 265.13% | 121.77% | 84.79% | 74.24% |
| Average Basic Shares Outstanding | 1.97% | 1.26% | 1.07% | 3.07% | 5.26% |
| Average Diluted Shares Outstanding | 5.95% | 3.43% | 1.67% | 3.08% | 5.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |